List of Antibody Drugs
Jump to navigation
Jump to search
| Antibody | Company * | Target | Indication | Source | Approval * |
|---|---|---|---|---|---|
| 3F8 | Memorial Sloan-Kettering Merck | GD2 | Detection and treatmenf of neuroblastoma | MOUSE; also with 124I or 131I | Clinical trials |
| Abciximab (ReoPro®) | Centocor B.V. Eli Lilly& Co. | Platelet glycoprotein GPIIb/IIIa. | High risk angioplasty | CHIMERIC Fab fragment | FDA 1994 |
| Abagovomab | Menarini | Act as surrogate antigen | Ovarian cancer | MOUSE anti-idiotype | Clinical trials |
| Adalimumab (Humira ® Trudexa®) | Abbott Laboratories | TNFα | Autoinmune disorders like arthritis reumatoid, psoriasis, Crohn's disease | HUMAN | FDA 2002 EMEA 2003 |
| Adecatumumab (MT201) | Micromet (MITI) | EpCAM-CD326 | Tumor cells (prostate, breast cancers) | HUMAN | Clinical trials |
| Afelimomab(Segard ™) | BASF, Abbot laboratories | TNFα | Sepsis | MOUSE (Fab')2 fragment | Failure of clinical trials |
| Afutuzumab (Obinutuzumab) (GA-101, RO5072759) | Hoffmann-La Roche | CD20 | Lymphoma | HUMANIZED | Clinical trials |
| Alacizumab pegol (CDP791, gl65 DFM-PEG) | Celltech, UCB | VEGFR2 | Non-small cell lung cancer | HUMANIZED F(ab')2 fragment- pegylated | Phase II Clinical trials |
| ALD518 (BMS-945429) | Alder Biopharmaceuticals, Inc. / Bristol-Myers Squibb | IL-6 | Rheumatoid arthritis | HUMANIZED aglycosylated | Phase II Clinical trials |
| Alemtuzumab (Campath-1H®; MabCampath®) | Genzyme | CD52 | Chronic lymphocytic leukaemia; T cell lymphoma | HUMANIZED | FDA 2001 EMEA 2001 |
| Altumomab pentetate (Hybri-CEAker™) | Hybritech incorporated | CEA | Diagnosis of colorectal cancer | MOUSE- pentetate-l11In | FDA orphan product 1990 |
| Anatumomab mafenatox (ABR-214936) | Active Biotech | Glycoprotein 5T4 | Non-small cell lung cancer | MOUSE Fab fragment-superantigen staphylococcal enterotoxin E | Phase II Clinical trials |
| Anrukinzumab (IMA-638) | Wyeth Pharmaceuticals | IL-13 | Asthma, colitis ulcerosa | HUMANIZED | Clinical trials |
| Apolizumab (HulDIO, REMITOGEN™ SMART™) | PDL (Protein Design Labs) BioPharma | HLA-DR β | Non-Hodgkin lymphoma, Chronic lymphocytic leukemia | HUMANIZED | Phase II Clinical trials |
| Arcitumomab (CEA-Scan®) | Immunomedics Inc. | Carcinoembrionic antigen | Detection of tumors | MOUSE Ig Fragment- 99mTc | FDA 1996 EMEA1996 Retired 2005 |
| Aselizumab | ? | CD62L | Immunosuppressive drug | HUMANIZED | Clinical trials |
| Atlizumab (Tocilizumab) (Actemra®, RoActemra®) | Hoffman-la Roche Chugai Pharmaceuticals | IL-6 receptor | Rheumatoid arthritis | HUMANIZED | EMEA 2009 FDA 2010 |
| Atorolimumab | ? | Rhesus factor | Immunosuppresive drug | HUMAN | ? |
| Bapineuzumab | Wyeth / Elan / Pfizer / J&J | β amyloid plaques | Alzheimer's disease/glaucoma | HUMANIZED | Clinical trials |
| Basiliximab (Simulect ®) | Novartis Phamaceutical Corp. | CD25 | Prevent rejection in organ transplantation | CHIMERIC | FDA 1998 EMEA 1998 |
| Bavituximab | Peregrine Pharmaceuticals, Inc | Phosphatidylserine | Cancer, viral infections | CHIMERIC | Clinical trials |
| Bectumomab (LymphoScan®) | Immunomedics, Inc | CD22 | Non-Hodgkin lymphoma | MOUSE Fab'fragment- 99mTc | ? |
| Belimumab (LymphoStat-B) (Benlysta®) | Human Genome Sciences GSK | BAFF (B cell activation factor) | systemic lupus erythematosus | HUMAN | FDA 2011 |
| Benralizumab (BIW-8405, MEDI-563) | Medlmmune Inc. | CD125 (IL-5 receptor) | Asthma | HUMANIZED | Phase II Clinical trials |
| Bertilimumab (CAT-213) | Cambridge Antibody Technology; Ico Therapeutics | CC111 (Eotaxinl) | Severe allergic disorders | HUMAN | Clinical trials |
| Besilesomab (Scintimun®) | Bayer Schering Pharma A. / CIS bio international | Carcinoembrionic antigen | Metastasis and inflammatory lesions | MOUSE- 99mTc | EMEA 2009 |
| Bevacizumab (Avastin®) | Genentech Inc./ Roche | VEGF-A | Cancer, age related macular degeneration | HUMANIZED | FDA 2004 EMEA 2005 |
| Biciromab(l11In) (FibriScint™) | Centocor | Fibrin II, β chain | Thromboembolism diagnosis | MOUSE Fab'fragment-111In | Withdrawn during clinical trials |
| Bivatuzumab mertansine | Boehringer Ingelheim | CD44 v6 | Squamous cell carcinoma | HUMANIZED-mertansine | Clinical trials |
| Blinatumomab | Micromet Inc, Medlmmune | CD19/CD3 | Non-Hodgkin lymphoma, acute lymphoblastic leukemia | MOUSE | Orphan drug (EME A/FDA) |
| Brentuximab vedotin (SGN-35 and previously cAOO-vcMMAE) | Seattle Genetics and Millennium | CD30 | Anaplastic large cell lymphoma; Hodgkin lymphoma | CHIMERIC (mouse/human)-auristatine | Clinical trials |
| Briakinumab (ABT-874) | Cambridge Antibody Technology; Abbott Laboratories | IL-12andIL-23 | Psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. | HUMAN | Clinical trials Ozespa, withdrawn for EMA |
| Canakinumab (Ilaris®) | Novartis Phamaceutical Corp. | IL-1β | Ceryopyrin-associated periodic syndromes | HUMAN | FDA 2009 EMEA 2009 |
| Cantuzumab mertansine (huC242-DMl, SB408075) | GlaxoSmithKline / ImmunoGen Inc. | Mucin CanAg | Colorectal tumor, Pancreatic cancers | HUMANIZED-mertansine | Phase I/II Clinical trials |
| Capromab Pendetide (111In) (ProstaScint®) | Cytogen Corp. | Prostate antigen | Detection of prostate tumor. | MOUSE-pentetide-111In | FDA 1996 |
| Catumaxomab (Removab®) | TRION Pharma | EpCAM and T cells- | Malignant ascitis with EpCAM-positive carcinomas | trifuncional antibody | EMEA 2009 |
| 125I-CC49 | ? | TAG-72 | Detection of tumors | MOUSE-125I | no tumour response, in Phase I and II trials |
| Cedelizumab (ORTHOCLONE OKT4 A) | Centocor Ortho Biotech Products LP | CD4 | Prevention of organ transplant rejections and the treatment of autoimmune diseases | HUMANIZED | Phase II Clinical trials |
| Certolizumab pegol (Cimzia®) | UCB | TNFα | Morbus Crohn, rheumatoid arthritis | HUMANIZED Fab-pegylated | FDA 2008 |
| Cetuximab, C-225 (Erbitux®) | Imclone Systems/ Bristol-Myers Squibb/ Merck KgaA | EGFR | Colorectal, Head and neck cancer | CHIMERIC | FDA 2004 EMEA 2004 |
| ch-TNT | Shanghai Medipharm Biotech | DNA associated antigens | Advanced lung cancer | CHIMERIC-131I | China 2003 |
| Citatuzumab bogatox VB6-845 | TACSTD1 | Ovarian cancer, solid tumors | HUMANIZED Fab fragment-bouganin | Pre-clinical trials | |
| Cixutumumab | Imclone Systems | IGF-1 receptor | Solid tumors | HUMAN | Clinical trials |
| Clenoliximab | CD4 | Rheumatoid arthritis | CHIMERIC (primate/human) | ||
| Clivatuzumab tetraxetan yttrium (90 Y) | Immunomedics Inc. | MUC1 | Pancreatic cancer | HUMANIZED | Phase II Clinical trials |
| Conatumumab (AMG-655) | Amgen | TNFRSF10B, TRAIL-R2 (CD262) | Solid tumors | HUMAN | Clinical trials |
| CR6261 | The Scripps Research Institute, Crucell | Influenza A hemagglutinin | Influenza virus infection | HUMAN | Preclinical trials |
| Dacetuzumab (SGN 40 or huS2C6) | Seattle Genetics | CD40 | Non- Hodgkin's lymphoma and hematological malignancies | HUMANIZED | Clinical trials |
| Daclizumab (Zenapax®) | Hoffman-La Roche | CD25 (IL-2 receptor) | Refractory unstable angina. Allograft rejection | HUMANIZED | FDA 1997 EMEA 1999 |
| Daratumumab | Genmab | CD38 | Multiple myeloma | HUMAN | Clinical trials |
| Denosumab XGEVA (Prolia®) | XGEVA, Amgen | RANKL | Postmenopausal osteoporosis | HUMAN | FDA 2010 EMEA 2010 |
| Detumomab | ? | B cell lymphoma | B cell lymphoma | MOUSE | ? |
| Ecromeximab (KW2871) | Kyowa Hakko Kogyo Co., Ludwig Institute for Cancer Research | GD3 ganglioside | melanoma | CHIMERIC (mouse/human) | Phase I/II Clinical trials |
| Eculizumab (Soliris®) | Alexion Pharmaceuticals | C5 Complement factor | paroxysmal nocturnal hemoglobinuria | HUMANIZED | FDA 2007 EMEA 2007 |
| Edobacomab (E5, XMMEN-0E5) | Pfizer | Endotoxin | Sepsis | MOUSE | Clinical trials |
| Edrecolomab (Panorex®) | Imaging Sciences L1c | EpCAM (17-1A) | Colorectal cancers | CHIMERIC | German approval 1995 |
| Efalizumab (Raptiva®) | Genentech Inc./ Roche | CDlla | Psoriais | HUMANIZED | FDA 2003. Recommended suspension. Withdrawn from market 2009 |
| Efungumab (Mycograb®) | NeuTec Pharma (Novartis) | Fungal HSP90 | Candida infection | HUMAN single chain variable fragment (scFv) | Discontinued the development on 2010 |
| Elotuzumab (HuLuc63) | PDL BioPharma Bristol Myers | SLAMf7(CD319) | Multiple myeloma | HUMANIZED | Clinical trials |
| Elsilimomab (B-E8) | ? | IL-6 | Lymphoma/Myeloma | MOUSE | preliminary Clinical trials |
| Enlimomab pegol | Boehringer Ingelheim Pharmaceuticals | ICAM-1 (CD54) | Immunomodulator, renal transplant rejection | MOUSE | Clinical trials |
| Epitumomab cituxetan 90Y | ? | Episialin | Several type of cancers. Epithelial Ovarian cancers | MOUSE- 90Y | Phase II |
| Epratuzumab | UCB and Immunomedics | CD22 | Autoinmune disorders such as lupus, Cancer | HUMANIZED | Clinical trials |
| Erlizumab (rhuMAbCD18) | Genentech/Roche | CD18 | Heart attack, stroke, traumatic shock | HUMANIZED F(ab')2fragment | Dropped |
| Ertumaxomab (Rexomun®) | Fresenius Biotech GmbH / TRION Pharma | HER2/neu, CD3 | Breast cancer | RAT/MOUSE HYBRID trifucntional antibody | Phase II Clinical trials |
| Etaracizumab o Etaratuzumab MEDI-522 (Abegrin® or Vitaxin) | Medlmmime, Inc. | Integrin αv β3 | Several type of cancers | HUMANIZED | Clinical trials |
| Exbivirumab | ? | Hepatitis B surface antigen | Hepatitis B infections | HUMAN | Preclinical |
| Fanolesomab (NeutroSpec™) | Palatin Technologies | CD15 | Apendicitis | MOUSE IgM-99mTc- | FDA 2004 Suspended in 2005 |
| Faralimomab | ? | Interferon receptor | Immunomodulator | MOUSE | ? |
| Farletuzumab (MORAb-003) | Morphotek | FR-α | Ovarian cancer | HUMANIZED | Phase III Clinical trials |
| Felvizumab (SB 209763) | Centocor Inc. / GlaxoSmithKline | Respiratory syncytial virus | Infection by RSV | HUMANIZED | Phase III Clinical trials |
| Fezakinumab (ILV-094) | Wyeth - Pfizer | IL-22 | Rheumatoid arthritis, psoriasis | HUMAN | Phase II Clinical trials |
| Figitumumab (CP-751871) | Pfizer | IGF-1 receptor | Various types of cancers | HUMAN | Clinical trials |
| Fontolizumab (HuZAF-™) | Novartis Pharmaceuticals Corp. / PDL (Protein Design Labs) BioPharma | Interferon γ | Auto-immune diseases like Crohn's disease | HUMANIZED | Rheumatoid Arthritis dropped, Phase II Clinical trials |
| Foravirumab (CR4098) | Crucell | Rabies virus glycoprotein | Infection by rabies virus | HUMAN | Phase II Clinical trials |
| Fresolimumab | Genzyme | TGF β | Pulmonar fibrosis/cancer | HUMAN | Clinical trials 2009 |
| Galiximab (IDEC-114) | Biogen Idee | CD80 | B cell lymphoma, Non-Hodgkin's lymphoma, Psoriasis | CHIMERIC (primate/human) | Phase I/II Clinical trials |
| Gantenerumab (R1450) | F. Hoffmann-La Roche Ltd. | β amyloid | Alzheimer's disease | HUMAN | Phase I Clinical trials |
| Gavilimomab (ABX-CBL) | Abgenix | CD 147 | Graft versus host disease | MOUSE | Phase II/III Clinical trials |
| Gemtuzumab ozogamicin (Mylotarg®,CMA-676) | Wyeth → Pfizer | CD33 | Relapsed acute myeloid leukaemia | HUMANIZED-Calicheamicin | FDA 2000 Suspended in US on 2010 |
| Girentuximab (Rencarex®cG250, WX-G250) | Wilex AG, Ludwig Institute for Cancer Research | Carbonic anhydrase 9 (CA-LX, MN, G250) | Renal carcinoma | CHIMERIC | Phase III Clinical trials |
| Girentuximab (Redectane®, 124I_cG250, 1241 WX-G250) | Wilex AG, Ludwig Institute for Cancer Research | Carbonic anhydrase 9 (CA-IX, MN, G250) | Renal mass, kidney tumors | CHIMERIC | Phase III Clinical trials |
| Glembatumumab vedotin(CR011,CDX-011) | Celldex Therapeutics, Inc. | GPNMB (transmembrane glycoprotein NMB) | Cancer cells expresing NMB: melanoma, breast cancer | HUMAN- Auristatin | Phase II Clinical trials |
| Golimumab (Simponi®) | J&J | TNFα | Rheumatoid arthritis, psoriatic arthritis and ankylosing spondulitis | HUMAN | FDA 2009 EMEA 2009 |
| Gomiliximab | IDEC Pharmaceuticals Corporation | CD23 | Allergic asthma | CHIMERIC (primate/human) | withdrawn |
| Ibalizumab (TMB-355) | Tanox; TaiMed Biologies | CD4 | HIV entry inhibitor | HUMANIZED | Clinical trials |
| Ibritumomab tiuxetan (Zevalin®) | Biogen IDEC Pharmaceuticals Corp. | CD20 | Non-Hodgkin lymphoma | MOUSE Ig- 90Y | FDA 2002 EMEA 2004 |
| Igovomab (Indimacis-125®) | CIS Bio international | MUC16CA-125 | Ovarian cancer | MOUSE conjugated to 111In | FDA 1996, EC withdrawal 1999 |
| Imciromab-Pentetate (Myoscint™) | Centocor | Heart myosin | Detection of heart disease | MOUSE conjugated to 111In | FDA Orphan product 1989; Withdrawn in 1993 |
| Infliximab (Remicade®) | Centocor (J&J) | TNFα | Psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. | CHIMERIC (mouse/human) | FDA 1998 /EMEA 1999 |
| Inolimomab | OPI (Orphan Pharma International) | IL2RA, CD25 | Graft-veraMi-host disease | MOUSE | Phase II/III Clinical trials |
| Inotuzumab ozogamicin (CMC-544) | Wyeth - Pfizer | CD22 | Diffuse large B cell lymphoma, Non-Hodgkin lymphoma | HUMANIZED -Calicheamicin | Phase II Clinical trials |
| Ipilimumab (MDX-101) (Yervoy™) | Bristol-Myers Squibb. | CD 152 (CTLA-4) | Activator of the immune system: late stage melanoma and other type of tumors | HUMAN | FDA 2011 |
| Iratumumab (MDX-060) | Medarex, Inc.- Bristol-Myers Squibb | CD30 | CD30-positive lymphoma including Hodgkin's disease | HUMAN | Phase II Clinical trials |
| Keliximab(IDECCE9.1/SB-210396) | Biogen IDEC Pharmaceuticals, SKB | CD4 | Immunosuppressor. Severe chronicAsthma, Rheumatoid arthritis | CHIMERIC (primate/human) | Phase III Clinical trials suspended |
| Labetuzumab (hMN14, CEACIDE™) | Immunomedics, Inc | CEA | Colorectal tumor | HUMANIZED | Phase I/II Clinical trials |
| Lebrikizumab (MILR1444A) | Roche-Genentech | IL-13 | Asthma | HUMANIZED | Phase II Clinical trials |
| Lemalesomab | ? | NCA-90 (granulocyte antigen) | Diagnosis of inflammatory lesions | MOUSE | ? |
| Lerdelimumab (CAT-152) | Cambridge Antibody Technology | TGF β | Immunosuppresor. Glaucoma | HUMAN | Phase III Clinical trials |
| Lexatumumab (ETR2-ST01) | HGS; Cambridge Antibody Technology | TRAIL-R2 (AP02) | Tumors | HUMAN | Clinical trials |
| Libivirumab | ? | Hepatitis B surface antigen | Hepatitis B infection | HUMAN | Preclinical |
| Lintuzumab | Seattle Genetics | CD33 | acute myeloid leukemia | HUMANIZED | Clinical trials |
| Lorvotuzumab mertansine IMGN901 | ImmunoGen, Inc | CD56 | Small cell lung cancer, ovarian cancer | HUMANIZED -mertansine | Orphan drug; clinical trials |
| Lucatumumab | Novartis Pharmaceuticals Corp | CD40 | Cancer like multiple myeloma, non-Hodgkin's or Hodgkin's lymphoma | HUMAN | Clinical trials |
| Lumiliximab(IDEC-152,P5E8) | Biogen IDEC Pharmaceutical | CD23 | Chronic lymphocytic leukaemia, Allergic asthma | CHIMERIC (primate/human) | Phase I/II Clinical trials |
| Mapatumumab | Cambridge Antibody Technology and Human Genome Sciences, Inc. | TRAIL-receptor (death receptor 4 | Several tumors | HUMAN | Clinical trials |
| Maslimomab | ? | T cell receptor | Immunosuppresor | MOUSE | ? |
| Matuzumab (EMD 72000) | Merck Serono; Takeda Pharmaceutical, | EGFR | Several tumors | HUMANIZED | Dropped |
| Mepolizumab | GlaxoSmithKline | IL-5 | Hypereosinophilic syndrome | HUMANIZED | Clinical trials |
| Metelimumab (CAT-192) | Cambridge Antibody Technology | TGF β1 | Scleroderma | HUMAN | Dropped |
| Milatuzumab | Immimomedics, Inc | CD74 | Multiple myeloma | HUMANIZED-doxorubicin | Clinical trials |
| Minretumomab | ? | TAG-72 | Cancer | MOUSE | ? |
| Mitumomab (BEC2) | ImClone Systems Inc./ Memorial Sloan-Kettering Cancer Center/Merck KgaA | GD3 ganglioside | Melanoma and Small cell lung carcinoma | MOUSE | Phase III Clinical trials |
| Morolimumab | ? | Rhesus factor | Immunosuppresor | HUMAN | ? |
| Motavizumab (Numax) | Medlmmune | RSV glycoprotein F | Prevention of respiratory syncitial inf. | HUMANIZED | FDA withdrawn 2010 |
| Muromonab-CD3. (Orthoclone OKT3™) | Ortho Biotech, Inc. (subsidiary of J&J) Janssen-Cilag | CD3 | Prevention of organ transplant rejection | MOUSE | FDA 1986 EMEA 1987 |
| Nacolomab tafenatox | ? | C242 | Colorectal tumor | MOUSE-enterotoxin A from Staphylococcus aureus | ? |
| Naptumomab estafenatox (ABR-217620, ANYARA, TTS CD3) | Active Biotech AB | TPBG (trophoblast glycoprotein, 5T4) | Several tumors | MOUSE Fab fragment-enterotoxin E from Staphylococcus aureus | Clinical trials |
| Natalizumab (Tysabri®) | Biogen Idee and Elan Corp. | Integrin α4 subunit ofa4β1 | Multiple Sclerosis, Chron's disease | HUMANIZED | FDA 2004/ withdrawn/ back on2006/ EMEA only for restricted cases |
| Nebacumab (centoxin, HA-1A. septomonab) | Centocor | Endotoxin | Sepsis | HUMAN | Withdrawn in 1993 |
| Necitumumab (IMC-11F8) | ImClone Systems Inc. | EGFR | Several tumors | HUMAN | Clinical trials |
| Nerelimomab | ? | TNFα | TNF inhibitor | MOUSE | ? |
| Nimotuzumab (BIOMab EGFR®) (TheraCIM) (TheraLoc) (CIMAher) | CIM, Cuba YM Biosciences, Out-licensed to other companies Daiichi Sankyo, Inc (ONLY JAPAN) | EGFR | Squamous cell carcinoma and glioma | HUMANIZED | Orphan drug FDA, EMEA 2004, Several countries 2005 China; 2006 India. |
| Nofetumomab merpentan (Verluma®) | Boehringer Ingelheim Pharma KG | Glycoprotein 40 kD | Detection of tumors | MOUSE Fab IgG2b-merpentan-99mTc | FDA 1996 |
| Ocrelizumab | Hoffman-La Roche Inc. | CD20 | Immunosuppresive drug | HUMANIZED | Clinical trials |
| Odulimomab. (afolimomab. ANTILFA®) | Pasteur-Merieux | integrin α L subunit -CDlla | Allograft Transplant rejection | MOUSE | Phase III, not renewed |
| Ofatumumab (Arzerra HuMax-CD20®) | Genmab | CD20 | Chronic lymphocytic leukemia | HUMAN | FDA 2009 EMEA 2010 |
| Olaratumab (IMC-3G3) | Imclone | PDGF-Rα | Solid tumors | HUMAN | Phase I Clinical trials |
| Omalizumab (Xolair®) | Genentech Inc./ Roche/ Tanox, Inc., Novartis Pharmaceuticals | IgE | Severe asthma. | HUMANIZED | FDA 2003 EMEA 2005 |
| Oportuzumab monatox. (PROXINIUM™ VICINIUM™) | Viventia Biotechnologies Inc. | EpCAM, and others | Several tumors | HUMANIZED (sc Fv)- Pseudomonas aeruginosa exotoxin A | Phase II/III Clinical trials |
| Oregovomab (OVAREX®) | AltaRex Corp | MUC16, CA-125 | Ovarian tumors | MOUSE | Phase II Clinical trials |
| Otelixizumab TRX4 | Tolerx, Inc. AND GlaxoSmithKline. Manufact. by Abbott Laboratories | CD3ε | Type 1 diabetes and other autoimmune diseases | CHIMERIC/HUMANIZED | Clinical trials. Orfan drug status FDA |
| Pagibaximab | Biosynexus, Glaxo Smith Kline | Staphylococcal lipoteichoic acid | Prevention of sepsis by staphylococcus | CHIMERIC (mouse/human) | Orphan drug status EMEA 2010 |
| Palivizumab (Synagis™) | Medimmune Inc. | An epitope of the RSV F protein | Respiratory syncitial virus infection | HUMANIZED | FDA 1998 EMEA 1999 |
| Panitumumab (ABX-EGF) (Vectibix™) | Amgen/Abgenix | Epidermal growth factor receptor (EGFR) | Metastatic colorectal carcinoma | HUMAN | FDA 2006 EMEA 2007 |
| Panobacumab (o Aerumab 11) (KBPA-101) | Kenta Biotech Ltd | Pseudomona aeruginosa serotype ATS 01l | Infection by pseudomona | HUMAN | Phase I/II Clinical trials |
| Pascolizumab | Centocor Inc. / GlaxoSmithKline | IL-4 | Allergy, Asthma | HUMANIZED | Phase II Clinical trials |
| Pemtumomab (Theragyn) | Antisoma pic Abbot Laboratories | MUC1 | Ovarian and peritoneal cancer | MOUSE | Clinical trials; orphan drug status in FDA and EMEA |
| Pertuzumab (Omnitarg™) | Genentech | HER2 | Tumors | HUMANIZED | Clinical trials |
| Pexelizumab | Procter & Gamble (P&G) Alexion Pharmaceuticals | C5 Complement component | Reduce side effects of coronary artery bypass grafting and angioplasty | HUMANIZED | Disappointing results on phase III. |
| Pintumomab technetium -99mTc | ? | Adenocarcinoma antigen | Imaging of adenocarcinoma | MOUSE-99mTc | ? |
| Priliximab | Centocor | CD4 | Crohn's disease and multiple sclerosis | CHIMERIC (mouse/human) | pending |
| Pritumumab | Nascent Biologies, Inc. | Vimentin | Brain cancer | HUMAN | Clinical trials |
| Pro 140 | Progenies Pharmaceuticals | CCR5 | HIV infection | HUMANIZED | Clinical trials/ fast track approval |
| Rafivirumab (CR57) | Crucell | Rabies virus glycoprotein | Rabies profilaxis | HUMAN | Phase II Clinical trials |
| Ramucirumab (IMC-1121B) | Pfizer/ImClone Systems Inc | VEGFR-2 | Several tumors | HUMAN | Clinical trials. |
| Ranibizumab (Lucentis®) | Genentech Inc. (Roche) / Novartis | Vascular endothelial growth factor A (VEGF-A) | Wet Macular degeneration | HUMANIZED Fab | FDA 2006 EMEA 2007 |
| Raxibacumab (ABthrax) | Human Genome Sciences | Protective antigen of anthrax toxin | Antrax toxin | HUMAN | Phase III Clinical trials |
| Regavirumab | Teijin | Cytomegalovirus glycoprotein B | Cytomegalovirus infection | HUMAN | Phase I Clinical trials |
| Reslizumab | Ception Therapeutics, Inc | IL-5 | Eosinophil-meditated inflammations | HUMANIZED (from rat) | Phase II Clinical trials |
| Rituximab (Rituxan®) (MabThera®) | Roche / Biogen Idee | CD20 | Non-Hodgkin lymphomas, rheumatoid arthritis | CHIMERIC | FDA 1997 EMEA 1998 |
| Robatumumab (SCH 717454) | Schering-Plough. | CD221 | Colon sarcoma, Blood cancers | HUMAN | Preclinical and Phase II Clinical trials |
| Rontalizumab | Genentech Inc. | IFNα | Systemic lupus erythematosus | HUMANIZED | Clinical trials. |
| Rovelizumab (LeukArrest, Hu23FG2) | Icos | CD11,CD18 | Immunosuppresive drug | HUMANIZED | FDA 1998, dropped 2000 |
| Ruplizumab (Antova™) | Biogen Idee Ma Inc. | CD154 | Rheumatic diseases | HUMANIZED | FSA fast tracked |
| Satumomab pendetide (OncoScint CR103™) | Cytogen Corp. and Cetus Corp, Lonza Biologies | TAG-72 | Ovarian and Colorectal Cancer diagnosis | MOUSE-pentetide- 11lIn | Withdrawn |
| Sevirumab (MSL-109) (Protovir™) | Novartis Pharmaceuticals Corp. / PDL (Protein Design Labs) BioPharma | CMV | Cytomegalovirus infection in AIDS patients | HUMAN | Phase III |
| Sibrotuzumab | ? | FAP | Tumors | HUMANIZED | |
| Siltuximab | Centocor Inc. | IL-6 | Multiple myeloma and other Tumors | CHIMERIC (mouse/human) | Phase II Clinical trials |
| Siplizumab (MEDI-507) | BioTransplant, Medlmmune Inc. | CD2 | Psoriasis and in the prevention of graft-verms - host disease, and Acute kidney transplant rejection | HUMANIZED (from rat) | Phase II Clinical trials |
| Solanezumab | Eli Lilly | βamyloid | Alzheimer's disease | HUMANIZED | Phase II Clinical trials |
| Stamulumab (MYO-029) | Cambridge Antibody Technology, Wyeth Pharmaceuticals | Myostatin | Muscular distrophy | HUMAN | Phase I/II Clinical trials |
| Sulesomab-Technetium (Leukoscan®) | Immunomedics Inc, Nycomed GmbH | NCA-90 (granulocyte cell antigen | Detection of inflammation, diagnosing osteomyelitis | MOUSE- 99mTc | marketed in European Union |
| Tacatuzumab tetraxetan-yttrium (90Y) (AFP-Cide) | Immunomedics Inc. | α fetoprotein (AFP) | Cancers | HUMANIZED-tetraxetan-90y | withdrawn |
| Tadocizumab (C4Gl,YM-337) | Yamanochi Pharma America, PDL (Protein Design Labs) BioPharma | Integrin αIIbβ3 | Percutaneous coronary interventions | HUMANIZED Fab | Phase II Clinical trials |
| Talizumab (TNX-901) | Tanox, Novartis | Fc region of IgE | Allergy reactions | HUMANIZED | withdrawn |
| Tanezumab (RN624) | Pfizer | Nerve growth factor (NGF) | Pain treatment | HUMANIZED | Clinical trials |
| Taplitumomab paptox | ? | CD19 | Tumors | MOUSE- conjugated with antiviral protein PAP from Phytolacca americana | ? |
| Tefibazumab (Aurexis®) | Inhibitex | Clumping factor A | Severe infectious with Staphylococcus a. | HUMANIZED | Clinical trials |
| Telimomab aritox | ? | Immunosuppresive drug | MOUSE (Fab fragment)-ricin protein | 1991, phase I, discontinued | |
| Tenatumomab | Sigma-Tau | Tenascin C | Cancer | MOUSE | ? |
| Teneliximab | ? | CD40 | Immunosuppresive drug | CHIMERIC (mouse/human) | ? |
| Teplizumab MGA031 | Eli Lilly | CD3 | Diabetes mellitus type 1 | HUMANIZED | Phase III disappointed |
| TGN1412 (CD28-superMAB) | TeGenero Immuno Therapeutics | CD28 | B cell chronic lymphocytic leukemia (B-CLL) and rheumatoid arthritis, | HUMANIZED | Catastrophic systemic organ failure 2006 on phase I |
| Tigatuzumab (CS-1008) | Daiichi Sankyo, Inc | TRAIL-R2 OrDR5 | Several tumors (colorectal, pancreas, ovary) | HUMANIZED | phase II Clinical trials |
| TNX-650 | Tanox | IL-13 | Refractory Hodgkin's lymphoma | HUMANIZED | Clinical trials |
| Tocilizumab o atlizumab (Actemra®) | Hoffman-la Roche; Chugai Pharmaceuticals. | IL-6 receptor | Rheumatoid arthritis | HUMANIZED | EMEA 2009 FDA 2010 |
| Toralizumab (IDEC 131) | IDEC Pharmaceuticals Corporation | CD154 (CD40 ligand) | Immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis) | HUMANIZED | Trials halted on Phase II |
| Tositumomab (Bexxar®) | Corixa Corp and GlaxoSmithKline | CD20 | Non-Hodgkin follicular lymphoma | Mouse Ig-131I | FDA 2003 |
| Trastuzumab (Herceptin®) | Genentech Inc. (ROCHE) | ErbB2 (HER2/neu) | Breast cancer | HUMANIZED | FDA 1998 EMEA 2000 |
| Tremelimumab o Ticilimumab (CP-675,206) | Pfizer | CD 152 (CTLA-4) | Melanoma/small cell lung cancer/prostate cancer | HUMAN | Clinical trials |
| Tucotuzumab celmoleukin | EMD pharmaceuticals | EpCAM | Several tumors | HUMANIZED- celmoleukin (IL-2) | Clinical trials |
| Tuvirumab | PDL (Protein Design Labs) BioPharma | Hepatitis B virus | Chronic hepatitis B | HUMAN | Phase I clinical trials in 2001 |
| Urtoxazumab | TMA-15 TEIJIN | E coli Shiga like toxin II B (STEC 0-157 infection) | Diarrhoea by Escherichia coli (serotype 0121) | HUMANIZED | Phase II Clinical trials |
| Ustekinumab (Stelara®) | J&J | P40fromIL-12 and IL-23 | Psoriasis, multiple sclerosis | HUMAN | FDA 2009 EMEA 2008 |
| Vapaliximab | (HUVAP) Biotie Therapies (VAP-1 fully human) Turku-Finland | Vascular adhesion protein (VAP-1) | Inflammation | CHIMERIC (mouse/human) | Phase I (2002) |
| Vedolizumab | Millennium Pharmaceuticals | Integrin α4β7 | Ulcerative colitis and Crohn's disease | HUMANIZED | Clinical trials |
| Veltuzumab | Immunomedics, Inc | CD20 | Non-Hodking's lymphoma | HUMANIZED | Clinical trials |
| Vepalimomab (vepalimomabum) | Biotie Therapies (VAP-1 fully human) | Vascular adhesion protein (VAP-1) | Inflammation | MOUSE HUMAN | Phase 2 enabling work underway.(Scifinder)Immunoglobulin M, anti-(human vascular adhesion protein VAP-1)(mouse monoclonal 1B2μchain) disulfide with mouse monoclonal 1B2 light chain, dimer |
| Visilizumab (Nubion) | PDL BioPharma Inc | CD3 | Multiple myeloma and diabetes mellitus type 1 | HUMANIZED | Clinical trials |
| Volociximab | PDL BioPharma and Biogen Idee | Integrin α5β1 | Solid tumors | CHIMERIC(mouse/human) | Clinical trials |
| 99mTc -Votumumab (HumaSPECT®) | KS Biomedix Ltd, Non commercialized | CTAA16.88 cytokeratin polypeptides | Detection of colorectal tumor. Diagnostic imaging | HUMAN- 99mTc | EC withdrawal |
| Zalutumumab (HuMax-EGFR) | GenMab | EGFR | Squamous cell carcinoma resistant to chemotherapy | HUMAN- BSC | Clinical trials |
| Zanolimumab (HuMax-CD4) | GenMab | CD4 | Rheumatoid arthritis/psoriasis/melanoma/T cell lymphoma | HUMAN | Clinical trials |
| Zolimomab aritox | XOMA Corp CD5 Plus; H65-RTA; Orthozyme CD5plus; XZ-CD5; XomaZyme-H65 | CD5 | Systemic lupus erythematosus / graft versus host disease | MOUSE-ricin protein | the studies failed to show positive effects(Immunotoxin) |